EIKON THERAPEUTICS INC (EIKN)

Health Care · biotechnology · NASDAQ

Eikon Therapeutics is an oncology-focused biopharmaceutical company advancing a clinical pipeline of novel immune-oncology and DNA damage response candidates discovered through its proprietary research platform.

View SEC filings Filings archive → Large price moves → Website Find companies like EIKN → Ask about EIKN →

What EIKON THERAPEUTICS INC does

Eikon Therapeutics is a clinical-stage biopharmaceutical company focused on developing a pipeline of oncology therapeutics. The company utilizes a proprietary research platform to discover and advance small-molecule candidates, including TLR 7/8 dual-agonists and selective PARP1 inhibitors, aimed at addressing serious unmet medical needs in cancer.

Recent developments

Eikon recently reported positive interim progress on the TeLuRide-006 Phase 2/3 registrational trial for EIK1001 in advanced melanoma and initiated the TeLuRide-008 trial for first-line NSCLC. The company also has seven abstracts accepted for presentation at the ESMO Congress 2026 covering its full clinical portfolio.

From EIKON THERAPEUTICS INC's filing of 2026-08-13.

Themes: oncology, immune-oncology, DNA damage response, clinical-stage biotech

Fundamentals

Price$7.50 as of 2026-10-08 close
Market cap$406M as of 2026-08-03 (share count; price 2026-10-08)
P/En/a earnings data not available
Debt / equity0.00 as of 2026-09-03
Beta1.90 as of 2026-09-03
Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)

Ask why EIKN looks like this →

How EIKON THERAPEUTICS INC looks technically

EIKON THERAPEUTICS INC (EIKN): a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 35, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 5 trading days ago.

Trend

Distance from the 200-day	not enough price history yet — needs 200 trading sessions	n/a
50-day moving average	its average price over the last 50 trading days — a short-term trend line — is $9.63	$9.63
200-day moving average	not enough price history yet — needs 200 trading sessions	n/a
Swing structure	each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next	higher highs and higher lows
Last swing turn	its last significant turn was a swing low 37 calendar days ago — the swings before that are what the structure reading is measured on	37 sessions
Since the 50/200 cross	not enough price history yet — needs 200 trading sessions	n/a
Trend strength (14-day ADX)	a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend)	21.2

Momentum

14-day RSI	momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 35, neither overbought (above 70) nor oversold (below 30)	34.8
Position in its 14-day range	it is trading in the lower half of its 14-day range ($7.01 to $9.33) — its "stochastic" reading is 21 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions.	21.0
Since the MACD crossed zero	MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish)	28 sessions

Range

Since a 20-day breakout	it made a new 20-day low about 5 trading days ago	5 sessions
Since a 55-day breakout	it made a new 55-day low about 5 trading days ago	5 sessions
All-time high	its highest closing price on record is $17.40 (set on 2026-02-05)	$17.40
Given back of the 52-week move	not available for this company yet	n/a
Nearest price level	not enough price history yet — needs 252 trading sessions	n/a
All-time low	its lowest closing price on record is $7.01 (set on 2026-10-05)	$7.01
Above the all-time low	it is 6.9% above its all-time low	+6.9%

Volatility

Band width vs its own 6 months	day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 84% of it)	16th percentile
Typical daily range	in a typical session it travels about $0.6747 between its high and its low — about 9.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was	$0.6747
Bollinger bands (20-day, ±2σ)	most of its recent trading has stayed between about $6.90 and $9.57 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles	$6.90 – $8.23 – $9.57
Typical daily range (% of price)	its price moves about 9.0% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price	9.0%

Volume

Volume vs its 30-day average	trading volume is about normal versus its 30-day average	1.41×

Analyst

Change in the average price target	analysts' average price target is unchanged from the prior reading	0.0%
Change in the consensus rating	not available for this company yet	n/a

Candlestick patterns

Since a doji	today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level	today
Since a bearish engulfing	9 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it	9 sessions ago

Price gaps

Gap at the open	it opened on 2026-10-08 0.8% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close	-0.8%
Gap filled	a 2.5% gap down opened on 2026-10-07 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it	1 session ago

Price streaks

Closing streak	it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run	1 session down

Relative strength

vs market, 1 month	over the past 1 month this stock lagged the market by 31.0 percentage points (the stock lost 30.0% while the market gained 1.0%)	-31.0%
vs market, 3 months	over the past 3 months this stock lagged the market by 33.9 percentage points (the stock lost 30.0% while the market gained 3.8%)	-33.9%
vs market, 6 months	over the past 6 months this stock lagged the market by 38.0 percentage points (the stock lost 20.6% while the market gained 17.5%)	-38.0%
vs market, 12 months	not available for this company yet	n/a

Signal agreement

Bullish technical signals	0 of the 7 technical signals we can compute for it are currently in a bullish state — these describe past price behaviour, not a forecast	0 of 7
Bearish technical signals	3 of the 7 technical signals we can compute for it are currently in a bearish state: MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast	3 of 7

Trend (Ichimoku cloud)

Vs the Ichimoku cloud	trading 35% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thin, spanning 0.2% of the share price, which is taken to mean a barrier that gives way easily.	-35.4%

Volume-weighted price

Vs this year’s average price paid	the price is 32% below the average price paid since 2026-02-05, so the typical buyer over that stretch is under water. That average is $11.02 — a volume-weighted average of daily closes over 160 sessions, not a true tick-by-tick VWAP.	-31.9%
Vs the average paid since it last reported	the price is 21% below the average price paid since it last reported on 2026-08-13 (its 10-Q), so the typical buyer over that stretch is under water. That average is $9.51 — a volume-weighted average of daily closes over 40 sessions, not a true tick-by-tick VWAP.	-21.1%

Wave structure

No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.

Read from daily closes as of 2026-10-08.

An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.

Screens: Printed a doji candle · Most volatile (6%+ typical daily range) · Under water since its last earnings report (below the anchored VWAP) · Trading below the Ichimoku cloud | Learn: adx · rsi · breakout

Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.

Ask about EIKN's technicals →

Analyst consensus

Mean price target$24.60 range $4.00 – $32.00; median $29.00

Analyst estimates, as of 2026-10-08. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.

Analyst EPS estimate for EIKN

Consensus EPS estimate-$1.58 next reporting period, as of 2026-10-08
Estimate change, 30 days$0.00 from -$1.58, on 2026-09-03, 35-day window
Readings revised upward0% of 7 comparable readings

The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.

Ask how EIKN's estimates have moved →

Key risks (from latest filing)

["Heavy reliance on the success of its clinical product candidates, which are subject to rigorous regulatory review and clinical trial failure.","Significant cash burn and a requirement for additional capital to fund extensive R&D and ongoing clinical trials.","Intellectual property risks, including the ability to maintain patents and protect proprietary research technologies."]

See EIKN's biggest risks from its latest 10-Q →

Insider activity (SEC Form 4)

1 open-market purchase and 0 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-05. The 4 days since 2026-10-05 have not been checked yet.

Last 90 days · read to 2026-10-051 buy ($1M) · 0 sells — 1 buying insider
Last 180 days · read to 2026-10-051 buy ($1M) · 0 sells — 1 buying insider

Cluster buying: 3 different insiders reported open-market purchases (SEC code P) of EIKN within a 30-day window between 2026-02-04 and 2026-02-06. Disclosed Form 4 activity, not a prediction of performance or a buy signal.

Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)

Most recent open-market transaction: 2026-09-03. Based on Form 4 filings read through 2026-10-05; anything filed since is not yet included.

View full insider trading history → View SEC Form 3/4/5 filings

Ask about EIKN's insider activity →

Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.

Institutional ownership (13F)

5 institutional 13F filers reported holding EIKN as of 2026-06-30 (quarter-end position, filed within 45 days).

Distinct 13F filers 5
Reported shares held 9,682,267
Reported value $126,353,584

reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".

Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.

Ask about EIKN's institutional holders → See what each manager we track holds →

Short interest (FINRA)

EIKN had 5,452,560 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).

EIKN had 10.1% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.26 days to cover at the same settlement.

Reported short interest (shares) 5,452,560
Short interest (% of shares outstanding) 10.1%
Prior settlement (shares) 5,280,850
Reported change 3.25%
Days to cover (reported) 9.26

Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.

Ask about EIKN's short interest →

Competitors & peers

AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.

Not quite? Describe exactly what you want →

Compare EIKN vs…

EIKON THERAPEUTICS INC is found in…

Frequently asked questions

What does EIKON THERAPEUTICS INC (EIKN) do?

What sector is EIKON THERAPEUTICS INC (EIKN) in?

EIKON THERAPEUTICS INC (EIKN) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.

Who are EIKON THERAPEUTICS INC's (EIKN) competitors?

Notable peers of EIKON THERAPEUTICS INC (EIKN) include Merck, AstraZeneca, GSK, AbbVie and Pfizer. This peer set is informational only — not financial advice.

Is EIKON THERAPEUTICS INC (EIKN) overbought or oversold right now?

EIKON THERAPEUTICS INC (EIKN) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 35, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.

Where does stocks-llm's data on EIKN come from?

Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.

Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.

Last updated 2026-10-08.

Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.